Literature DB >> 10217535

Mechanisms of melatonin-induced vasoconstriction in the rat tail artery: a paradigm of weak vasoconstriction.

M J Lew1, S Flanders.   

Abstract

1. Vasoconstrictor effects of melatonin were examined in isolated rat tail arteries mounted either in an isometric myograph or as cannulated pressurized segments. Melatonin failed by itself to mediate observable responses but preactivation of the arteries with vasopressin (AVP) reliably uncovered vasoconstriction responses to melatonin with maxima about 50% of maximum contraction. Further experiments were conducted with AVP preactivation to 5-10% of the maximum contraction. 2. Responses to melatonin consisted of steady contractions with superimposed oscillations which were large and irregular in isometric but small in isobaric preparations. Nifedipine (0.3 microM) reduced the responses and abolished the oscillations. Charybdotoxin (30 nM) increased the magnitude of the oscillations with no change in the maximum response. 3. Forskolin (0.6 microM) pretreatment increased the responses to melatonin compared to control and sodium nitroprusside (1 microM) treated tissues. The AVP concentration required for preactivation was 10 fold higher than control in both the forskolin and nitroprusside treated groups. 4. In isometrically-mounted arteries treated with nifedipine, melatonin receptor agonists had the potency order 2-iodomelatonin > melatonin > S20098 > GR196429, and the MT2-selective antagonist luzindole antagonized the effects of melatonin with a low pK(B) of 6.1+/-0.1. 5. It is concluded that melatonin elicits contraction of the rat tail artery via an mt1 or mt1-like receptor that couples via inhibition of adenylate cyclase and opening of L-type calcium channels. Calcium channels and charybdotoxin-sensitive K channels may be recruited into the responses via myogenic activation rather than being coupled directly to the melatonin receptors. 6. It is proposed that the requirement of preactivation for overt vasoconstrictor responses to melatonin results from the low effector reserve of the melatonin receptors together with the tail artery having threshold inertia. Potentiative interactions between melatonin and other vasoconstrictor stimuli probably also result from the threshold inertia. A simple model is presented and a general framework for consideration of interactions between weak vasoconstrictor agonists and other vasoconstrictor stimuli is discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10217535      PMCID: PMC1565908          DOI: 10.1038/sj.bjp.0702435

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  Receptor reserve and threshold phenomena. I. Theory and experiments with autonomic drugs tested on isolated organs.

Authors:  E J ARIENS; J van ROSSUM; P C KOOPMAN
Journal:  Arch Int Pharmacodyn Ther       Date:  1960-09-01

2.  Melatonin receptors mediate contraction of a rat cerebral artery.

Authors:  M Viswanathan; E Scalbert; P Delagrange; B Guardiola-Lemaître; J M Saavedra
Journal:  Neuroreport       Date:  1997-12-22       Impact factor: 1.837

3.  Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats.

Authors:  M J Mulvany; W Halpern
Journal:  Circ Res       Date:  1977-07       Impact factor: 17.367

4.  Effect of melatonin in the rat tail artery: role of K+ channels and endothelial factors.

Authors:  G G Geary; S P Duckles; D N Krause
Journal:  Br J Pharmacol       Date:  1998-04       Impact factor: 8.739

5.  Melatonin mediates two distinct responses in vascular smooth muscle.

Authors:  S Doolen; D N Krause; M L Dubocovich; S P Duckles
Journal:  Eur J Pharmacol       Date:  1998-03-12       Impact factor: 4.432

6.  Identification of Mel1a melatonin receptors in the human embryonic kidney cell line HEK293: evidence of G protein-coupled melatonin receptors which do not mediate the inhibition of stimulated cyclic AMP levels.

Authors:  S Conway; J E Drew; S J Canning; P Barrett; R Jockers; A D Strosberg; B Guardiola-Lemaitre; P Delagrange; P J Morgan
Journal:  FEBS Lett       Date:  1997-04-21       Impact factor: 4.124

7.  Pre- and postjunctional effects of NPY on sympathetic control of rat femoral artery.

Authors:  J M Lundberg; J Pernow; K Tatemoto; C Dahlöf
Journal:  Acta Physiol Scand       Date:  1985-04

8.  Studies on the vasoconstrictor action of melatonin and putative melatonin receptor ligands in the tail artery of juvenile Wistar rats.

Authors:  K N Ting; W R Dunn; D J Davies; D Sugden; P Delagrange; B Guardiola-Lemaître; E Scalbert; V G Wilson
Journal:  Br J Pharmacol       Date:  1997-12       Impact factor: 8.739

9.  B-HT 920 acts as an alpha 1-adrenoceptor agonist in the rabbit aorta under certain in vitro conditions.

Authors:  I Lues; H J Schümann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

10.  The actions of prostaglandin E2 on potassium currents in rat tail artery vascular smooth muscle cells: regulation by protein kinase A and protein kinase C.

Authors:  J Ren; E Karpinski; C G Benishin
Journal:  J Pharmacol Exp Ther       Date:  1996-04       Impact factor: 4.030

View more
  3 in total

1.  A comparison of effects measured with isotonic and isometric recording: I. Concentration-effect curves for agonists.

Authors:  R B Barlow; S M Bond; C Grant; D S McQueen; Z Yaqoob
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  A comparison of effects measured with isotonic and isometric recording: II. Concentration-effect curves for physiological antagonists.

Authors:  R B Barlow; S M Bond; C Grant; D S McQueen; Z Yaqoob
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

Review 3.  Antioxidant Melatonin: Potential Functions in Improving Cerebral Autoregulation After Subarachnoid Hemorrhage.

Authors:  Zhen-Ni Guo; Hang Jin; Huijie Sun; Yingkai Zhao; Jia Liu; Hongyin Ma; Xin Sun; Yi Yang
Journal:  Front Physiol       Date:  2018-08-17       Impact factor: 4.566

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.